文献速递造血干细胞移植与细胞治疗

局部鲁索替尼治疗慢性皮肤移植物抗宿主病:单中心随机双盲自身对照2期试验

Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial.
PubMed 文献 · Lancet Haematol · 2026-09-16

局部鲁索替尼显示出显著临床活性和良好安全性。

要点

  • 3-5级治疗中出现不良事件包括中枢神经系统白血病、鼻窦炎和肺部感染各1例(4%),无治疗相关死亡。

核心结论

  • 局部鲁索替尼在活动性皮肤cGVHD中显示出显著临床活性和良好安全性,可能成为减少激素用量、皮肤定向的替代或二线治疗。

研究设计与样本

  • 单中心、随机、双盲、自身对照2期试验,在美国纽约纪念斯隆凯特琳癌症中心开展。
  • 纳入24例年龄≥12岁、有异基因造血干细胞移植史、临床和/或组织学确诊皮肤cGVHD且受累体表面积≥2%的患者。
  • 主要终点为第28天两侧受累皮损体表面积(BSA)的绝对差异,以占总体表面积百分比记录,在可评估患者中分析,采用校正混合效应回归控制基线两侧BSA差异。
  • 仅完成第28天访视的患者纳入主要终点分析;所有接受任何研究治疗的患者纳入安全性分析。

主要发现

  • 2019年6月28日至2022年9月8日随机分配24例患者,中位随访128天(IQR 90-280)。
  • 第28天23例可评估(1例因筛查访视后入住重症监护室未开始治疗)。

关键数值与推荐

  • 纳入标准包括皮肤cGVHD累及至少2%体表面积。

临床怎么用

  • 治疗28天可显著减少受累皮损体表面积,安全性良好,3-5级不良事件发生率低。

局限性

  • 单中心、样本量小(24例随机分配,23例主要终点可评估)。
  • 自身对照设计,仅评估28天短期疗效。
  • 仅纳入皮肤cGVHD(表皮或浅表硬化型),未评估其他类型cGVHD。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, is approved for both acute and chronic graft-versus-host disease (cGVHD), whereas the topical formulation is approved for atopic dermatitis and vitiligo. Topical corticosteroids remain the mainstay for cutaneous cGVHD but their use is limited by adverse effects. We aimed to evaluate the clinical activity and safety of ruxolitinib 1·5% cream for epidermal or superficially sclerotic cutaneous cGVHD. METHODS: In this single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial at Memorial Sloan Kettering Cancer Center (NY, USA), patients aged 12 years or older with history of allogenic haematopoietic stem cell transplantation, with clinically confirmed, histologically confirmed, or both, cutaneous cGVHD involving at least 2% body surface area were randomly assigned to the body side receiving topical ruxolitinib 1·5% cream twice daily for 28 days; placebo vehicle was applied to contralateral lesional skin as a control. The primary endpoint was the absolute day-28 between-side difference in affected lesional body surface area (BSA), recorded as percentage of total BSA on each assigned side and analysed in evaluable patients; baseline between-side BSA differences were controlled for with adjusted mixed-effects regression. Only patients who completed the day 28 visit were included in the primary endpoint analysis; all patients who received any study treatment were included in the safety analysis. The trial is closed to enrolment and registered with ClinicalTrials.gov, NCT03954236. The trial is complete. FINDINGS: Between June 28, 2019, and Sept 8, 2022, 24 patients were randomly assigned, with a median follow-up of 128 days (IQR 90-280). Median age was 47·5 years (IQR 32·5-67·5); 13 (54%) were female and 11 (46%) were male. At day 28, 23 patients were evaluable (one patient did not start treatment after screening visit due to intensive care unit admission). Mean affected lesional body surface area changed from 14·3% (SD 7·9) at baseline to 6·2% (6·7) with ruxolitinib and from 14·5% (8·0) to 10·4% (9·1) with placebo vehicle (difference -4·2 percentage points, 95% CI -6·8 to -1·5; p=0·0030); after adjustment for baseline between-side body surface are difference, the difference was -4·0 percentage points (-5·5 to -2·4; p<0·0010). Grade 3-5 treatment emergent adverse events were CNS leukaemia, sinusitis, and lung infection (one [4%] each); no treatment-related deaths occurred. INTERPRETATION: Topical ruxolitinib showed significant clinical activity and favourable harms profile in active cutaneous cGVHD. Ruxolitinib cream could represent a steroid-sparing, skin-directed alternative or second-line therapy, expanding treatment options for patients with cutaneous cGVHD. FUNDING: Incyte.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Markova A, Ostojić J, Rotemberg V, et al. Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial. Lancet Haematol. 2026. PMID: 42748944. doi:10.1016/S2352-3026(26)00201-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。